Prognostic Biomarker MCP-4 Triggers Epithelial-mesenchymal Transition the P38 MAPK Pathway in Ovarian Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 19

PMID 36531002

Authors

Siting Li

Yuexin Hu

Ouxuan Liu

Xiao Li

Bei Lin

Affiliations

Soon will be listed here.

Abstract

Background: Monocyte chemoattractant protein-4 (MCP-4/CCL13) is a proinflammatory factor that is overexpressed in various malignant tumors and may play an important role in tumor progression and metastasis. However, its role and mechanism of action in ovarian cancer remains unknown.

Methods: Immunohistochemistry (IHC) was performed to detect the expression of MCP-4 in ovarian cancer tissues, and the effect of MCP-4 on patient survival and prognosis was analyzed. Overexpression and suppression of MCP-4 in ovarian cancer cell lines were then established, and their effects on cell invasion, migration, and apoptosis were studied. ES-2 cell lines were employed to establish a peritoneal dissemination model in nude mice. Western blotting was performed to detect the expression of epithelial mesenchymal transition (EMT) markers and the p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway.

Results: MCP-4 was highly expressed in ovarian cancer tissues and its expression level was related to the prognosis of patients with ovarian cancer. MCP-4 overexpression promoted the migration and invasion of ovarian cancer cells but inhibited apoptosis. MCP-4 overexpression increased the expression of MMP-2, MMP-9, N-cadherin, vimentin and Bcl2/Bax and decreased the expression of E-cadherin. MCP-4 overexpression increased the phosphorylation of the p38 MAPK pathway. The inhibition of MCP-4 expression indicated an opposite trend. experiments have also confirmed that MCP-4 overexpression can promote metastasis of ovarian cancer.

Conclusion: MCP-4 promotes ovarian cancer progression through the p38 MAPK signaling pathway, and may be a potential biomarker and therapeutic target for ovarian cancer.

Citing Articles

Amlodipine inhibits Synaptotagmin-4's oncogenic activity on gastric cancer proliferation by targeting calcium signaling.

Huang W, Yang S, Deng M, Luo R, Liang H, Shen Y Funct Integr Genomics. 2024; 24(3):77.

PMID: 38632140 PMC: 11024009. DOI: 10.1007/s10142-024-01345-8.

Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer.

Hussain Z, Bertran T, Finetti P, Lohmann E, Mamessier E, Bidaut G Cell Commun Signal. 2024; 22(1):1.

PMID: 38167013 PMC: 10759487. DOI: 10.1186/s12964-023-01388-7.

CCL13 and human diseases.

Li L, Dai F, Wang L, Sun Y, Mei L, Ran Y Front Immunol. 2023; 14:1176639.

PMID: 37153575 PMC: 10154514. DOI: 10.3389/fimmu.2023.1176639.

References

Franzen B, Alexeyenko A, Kamali-Moghaddam M, Hatschek T, Kanter L, Ramqvist T . Protein profiling of fine-needle aspirates reveals subtype-associated immune signatures and involvement of chemokines in breast cancer. Mol Oncol. 2018; 13(2):376-391. PMC: 6360506. DOI: 10.1002/1878-0261.12410. View

Yasui H, Kajiyama H, Tamauchi S, Suzuki S, Peng Y, Yoshikawa N . CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway. Clin Exp Metastasis. 2019; 37(1):145-158. DOI: 10.1007/s10585-019-09993-y. View

Barinka C, Prahl A, Lubkowski J . Structure of human monocyte chemoattractant protein 4 (MCP-4/CCL13). Acta Crystallogr D Biol Crystallogr. 2008; 64(Pt 3):273-8. DOI: 10.1107/S0907444907066164. View

Griffith J, Sokol C, Luster A . Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014; 32:659-702. DOI: 10.1146/annurev-immunol-032713-120145. View

Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee C . A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019; 156(1):23-31. DOI: 10.1016/j.ygyno.2019.11.006. View

Okugawa Y, Toiyama Y, Mohri Y, Tanaka K, Kawamura M, Hiro J . Elevated serum concentration of monocyte chemotactic protein 4 (MCP-4) as a novel non-invasive prognostic and predictive biomarker for detection of metastasis in colorectal cancer. J Surg Oncol. 2016; 114(4):483-9. DOI: 10.1002/jso.24335. View

Ozga A, Chow M, Luster A . Chemokines and the immune response to cancer. Immunity. 2021; 54(5):859-874. PMC: 8434759. DOI: 10.1016/j.immuni.2021.01.012. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

You Z, Liu S, Du J, Wu Y, Zhang S . Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. J Oral Pathol Med. 2018; 48(3):201-205. DOI: 10.1111/jop.12807. View

10.

Huang C, Clayton E, Matyunina L, McDonald L, Benigno B, Vannberg F . Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy. Sci Rep. 2018; 8(1):16444. PMC: 6219522. DOI: 10.1038/s41598-018-34753-5. View

11.

Hussain S, Peng B, Cherian M, Song J, Ahirwar D, Ganju R . The Roles of Stroma-Derived Chemokine in Different Stages of Cancer Metastases. Front Immunol. 2021; 11:598532. PMC: 7783453. DOI: 10.3389/fimmu.2020.598532. View

12.

Ghebre M, Pang P, Diver S, Desai D, Bafadhel M, Haldar K . Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J Allergy Clin Immunol. 2018; 141(6):2027-2036.e12. PMC: 5986707. DOI: 10.1016/j.jaci.2018.04.013. View

13.

Wang L, Cao J, Zhang J, Wang B, Hu X, Shao Z . The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells. Med Oncol. 2015; 32(11):254. DOI: 10.1007/s12032-015-0696-6. View

14.

Wang Z, Meng F, Zhong Z . Emerging targeted drug delivery strategies toward ovarian cancer. Adv Drug Deliv Rev. 2021; 178:113969. DOI: 10.1016/j.addr.2021.113969. View

15.

Lee E, Lilja S, Li X, Schafer S, Zhang H, Benson M . Bulk and single cell transcriptomic data indicate that a dichotomy between inflammatory pathways in peripheral blood and arthritic joints complicates biomarker discovery. Cytokine. 2019; 127:154960. DOI: 10.1016/j.cyto.2019.154960. View

16.

C Mok S, Bonome T, Vathipadiekal V, Bell A, Johnson M, Wong K . A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009; 16(6):521-32. PMC: 3008560. DOI: 10.1016/j.ccr.2009.10.018. View

17.

Dalgard C, Eidelman O, Jozwik C, Olsen C, Srivastava M, Biswas R . The MCP-4/MCP-1 ratio in plasma is a candidate circadian biomarker for chronic post-traumatic stress disorder. Transl Psychiatry. 2017; 7(2):e1025. PMC: 5438024. DOI: 10.1038/tp.2016.285. View

18.

Singh A, Gray J . Chemokine signaling in cancer-stroma communications. J Cell Commun Signal. 2021; 15(3):361-381. PMC: 8222467. DOI: 10.1007/s12079-021-00621-7. View

19.

Chen X, Chen Y, Lin X, Su S, Hou X, Zhang Q . The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell. Curr Pharm Biotechnol. 2018; 19(6):506-513. DOI: 10.2174/1389201019666180713102656. View

20.

Korbecki J, Kojder K, Siminska D, Bohatyrewicz R, Gutowska I, Chlubek D . CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020; 21(21). PMC: 7665155. DOI: 10.3390/ijms21218412. View